Back to top
more

athenahealth, Inc. (ATHN)

(Delayed Data from NSDQ)

$134.99 USD

134.99
NA

0.00 (0.00%)

Updated Feb 11, 2019 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Athenahealth (ATHN) Beats Q3 Earnings Estimates

by Zacks Equity Research

athenahealth (ATHN) delivered earnings and revenue surprises of 10.20% and -2.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Becton, Dickinson (BDX) likely to gain from strong segmental contributions in fiscal Q4.

Will Flagship Impella Drive Abiomed's (ABMD) Q2 Earnings?

by Zacks Equity Research

Abiomed (ABMD) likely to gain from flagship Impella in Q2; a competitive industry is a headwind.

Athenahealth (ATHN) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

Athenahealth (ATHN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will athenahealth (ATHN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

athenahealth (ATHN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Veeva Launches Vault SiteDocs for Regulatory Documentation

by Zacks Equity Research

Veeva's (VEEV) Vault SiteDocs Platform conducts high-quality, compliant clinical trials with greater visibility to researchers.

    Varian (VAR) Buys Noona to Boost Oncology Software Services

    by Zacks Equity Research

    Varian's (VAR) latest move provides it significant exposure to the cloud-based oncology services market.

      Cerner's Millennium Platform Integrated at McLaren Hospital

      by Zacks Equity Research

      Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.

      Athenahealth (ATHN) Q3 Earnings Preview: What to Look Out For

      by Zacks Equity Research

      Athenahealth (ATHN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Here's Why You Should Hold on to athenahealth (ATHN) for Now

      by Zacks Equity Research

      athenahealth (ATHN) likely to gain from focus on cloud-based healthcare services.

      Here's Why You Should Hold on to Cerner (CERN) Stock for Now

      by Zacks Equity Research

      Cerner (CERN) likely to gain from focus on big-data based healthcare services.

        Veeva's Technology Partner Joins Verix to Boost CRM Platform

        by Zacks Equity Research

        Veeva Systems' (VEEV) focus on cloud-based services is likely to favor the stock.

          AngioDynamics (ANGO) Q1 Earnings Miss, '19 Sales View Up

          by Zacks Equity Research

          AngioDynamics (ANGO) sees soft segmental performances in Q1; international sales surge.

            Sweta Jaiswal headshot

            4 MedTech Stocks to Counter Mounting US-China Trade Tensions

            by Sweta Jaiswal

            In the wake of the impact of the U.S.-China trade war on the MedTech space, we have doubled down on some stocks which offer a safe haven to investors.

              Here's Why You Should Hold on to Allscripts (MDRX) Stock Now

              by Zacks Equity Research

              Strong prospects in Sunrise EHR platform to aid Allscripts (MDRX). However, intense competition in the MedTech space is a headwind.

                Cerner CommunityWorks Selected by Pershing Health System

                by Zacks Equity Research

                Cerner (CERN) witnesses consistent growth in the Electronic Health Record platform and Revenue Cycle Management solutions.

                  Baxter's (BAX) ALTAPORE Bioactive Bone Graft Gets FDA Nod

                  by Zacks Equity Research

                  Baxter's (BAX) offers a broad spectrum of surgical products, including bone grafts and substitutes that see lucrative market prospects.

                    Accuray's CyberKnife Manages Prostate Cancer Effectively

                    by Zacks Equity Research

                    Accuray's (ARAY) flagship CyberKnife is the only robotic radiotherapy system.

                      Here's Why You Should Buy Baxter International (BAX) Now

                      by Zacks Equity Research

                      Baxter's (BAX) raised guidance for 2018 and a series of approvals make it a promising investment pick.

                        RTI Surgical's (RTIX) TETRAfuse Wins Spine Technology Award

                        by Zacks Equity Research

                        RTI Surgical (RTIX) to receive the Spine Technology Award from Orthopedics This Week at the NASS 33rd Annual Meeting in Los Angeles.

                          Boston Scientific Thrives in Urology on New LithoVue Empower

                          by Zacks Equity Research

                          Boston Scientific's (BSX) combination of LithoVue Empower and LithoVue Single-Use Digital Ureteroscope will put the whole stone manipulation procedure in the operating surgeon's hands.

                            Quest Diagnostics Grows in Fertility Services With New Buyout

                            by Zacks Equity Research

                            Quest Diagnostics' (DGX) acquisition of ReproSource lies in tandem with the company's accelerated growth strategy, especially in advanced diagnostics.

                              Abiomed's Impella Ensures Higher Survival Rates, Shares Up

                              by Zacks Equity Research

                              Abiomed's (ABMD) Impella successfully treats patients with cardiogenic shocks; market prospects bright.

                                NextGen Rides on Prospects in RCM Space, Competition Rife

                                by Zacks Equity Research

                                NextGen (NXGN) is a major player in the U.S. RCM market. However, the company faces cutthroat competition in the healthcare information systems and services market.

                                  Here's Why You Should Invest in PRA Health (PRAH) Stock Now

                                  by Zacks Equity Research

                                  The CRO industry's bullish prospects currently make PRA Health (PRAH) a promising investment pick.